Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number: 3235-028											
Estimated average burden											
hours per response: 0											

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BRUM LYNNE H						2. Issuer Name and Ticker or Trading Symbol YIELD10 BIOSCIENCE, INC. [YTEN]								(Checl	ationship of Reportin c all applicable) Director Officer (give title		10% Ov Other (s		wner
(Last) C/O YIE 19 PRES	3. Date of Earliest Transaction (Month/Day/Year) 03/01/2021									X	below) below) VP Planning & Comms								
(Street) WOBUR (City)	4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									Form Form	Form filed by One Reporting Person Form filed by More than One Reporting Person							
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Trans: Date (Month/L						Exec if any	Deemed ecution Date, ny onth/Day/Year)		3. Transaction Code (Instr. 8)					, 4 and Seco Ben Owr		cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
						Code	v	Amount	(A) c (D)	r Pri	ice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common Stock 03/01					021			Α		2,092(1)	A	\$1	16.03	4,998		D			
Common Stock														3,206 ⁽²⁾			I	By 401(k) Plan	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Yea			3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y		ite	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Dei Sed (Ins	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V (A)			(D)	Date Exercis	able	Expiration Date	Title	Amour or Number of Shares	er					

Explanation of Responses:

- 1. The securities awarded are in the form of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 50% of the shares on 09/01/2021 and the remaining 50% on 03/01/2022.
- 2. Shares acquired as Company matching contributions under the Yield10 Bioscience, Inc. 401(k) Plan.

/s/ Megan N. Gates, attorney-

03/03/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.